VistaGen Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTGN research report →
Companywww.vistagen.com
VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.
- CEO
- Shawn K. Singh
- IPO
- 2011
- Employees
- 48
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $20.97M
- P/E
- -0.40
- P/S
- 26.54
- P/B
- 0.53
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.68%
- Op Margin
- -8847.85%
- Net Margin
- -8486.84%
- ROE
- -109.73%
- ROIC
- -133.08%
Growth & Income
- Revenue
- $486.00K · -54.32%
- Net Income
- $-51,418,000 · -75.12%
- EPS
- $-1.67 · -9.87%
- Op Income
- $-55,973,000
- FCF YoY
- -63.44%
Performance & Tape
- 52W High
- $5.14
- 52W Low
- $0.43
- 50D MA
- $0.60
- 200D MA
- $2.11
- Beta
- 0.30
- Avg Volume
- 767.70K
Get TickerSpark's AI analysis on VTGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Angelov Angel S | other | 150,000 |
| May 18, 26 | Angelov Angel S | other | 0 |
| Apr 7, 26 | Tressler Nick B. | other | 75,000 |
| Apr 7, 26 | Singh Shawn | other | 71,268 |
| Apr 7, 26 | Singh Shawn | other | 3,732 |
| Apr 7, 26 | Prince Joshua S. | other | 56,248 |
| Apr 7, 26 | Prince Joshua S. | other | 18,752 |
| Apr 7, 26 | Cote Elissa S. | other | 75,000 |
| Apr 7, 26 | Adler Reid G. | other | 56,247 |
| Apr 7, 26 | Adler Reid G. | other | 18,753 |
Our VTGN Coverage
We haven't published any research on VTGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VTGN Report →